Abstract
No adequate immunotherapy has so far been shown to be effective in anti-myelin-associated glycoprotein (MAG) antibody neuropathy.1 Rituximab was assessed in two randomised controlled trials, both including only patients with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have